UPDATE: SVB Leerink On Amgen: Firm Notes Encouraging Responses In Sotorasib Nave Subjects Given Overall Response Rate At 33% With Many Patients Remaining On Combination Treatment After Median Of 10.3 Weeks; Expects Phase 3 Trial To Start In 2H21